References

  1. Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition: a consensus statement from the international diabetes federation. Diabet Med J Br Diabet Assoc. 2006 May; 23(5): 469-80. PubMed | Google Scholar

  2. Alshehri AM. Metabolic syndrome and cardiovascular risk. J Fam Community Med. 2010 Aug; 17(2): 73. PubMed | Google Scholar

  3. Fox CS. Cardiovascular disease risk factors, Type 2 Diabetes Mellitus, and the Framingham Heart Study. Trends Cardiovasc Med. 2010 Apr; 20(3): 90. PubMed | Google Scholar

  4. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in Nondiabetic European Men and Women. Arch Intern Med. 2004 May 24; 164(10): 1066-76. PubMed | Google Scholar

  5. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001 Apr 1; 24(4): 683?9. PubMed | Google Scholar

  6. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002 Dec 4; 288(21): 2709-16. PubMed | Google Scholar

  7. Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the Metabolic Syndrome Improve Identification of Individuals at Risk of Type 2 Diabetes and/or Cardiovascular Disease. Diabetes Care. 2004 Nov 1; 27(11): 2676-81. PubMed | Google Scholar

  8. World Health Organization. Global action plan for the prevention and control of noncommunicable diseases: 2013-2020. Accessed on July 10 2017.

  9. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992 May; 74(5): 1045-52. PubMed | Google Scholar

  10. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS Lond Engl. 1998 May 7; 12(7): F51-58. PubMed | Google Scholar

  11. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26; 338(13): 853-60. PubMed | Google Scholar

  12. Ete T, Ranabir S, Thongam N, Ningthoujam B, Rajkumar N, Thongam B. Metabolic abnormalities in human immunodeficiency virus patients with protease inhibitor-based therapy. Indian J Sex Transm Dis. 2014; 35(2): 100-3. PubMed | Google Scholar

  13. Palacios R, Santos J, González M, Ruiz J, Márquez M. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy. Int J STD AIDS. 2007 Mar 1; 18(3): 184-7. PubMed | Google Scholar

  14. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. The Lancet. 2005 Sep; 366(9491): 1059-62. PubMed | Google Scholar

  15. Isezuo SA, Ezunu E. Demographic and clinical correlates of metabolic syndrome in Native African type-2 diabetic patients. J Natl Med Assoc. 2005 Apr; 97(4): 557. PubMed | Google Scholar

  16. Fezeu L, Balkau B, Kengne A-P, Sobngwi E, Mbanya JC. Metabolic syndrome in a sub-Saharan African setting: central obesity may be the key determinant. Atherosclerosis. 2007 Jul; 193(1): 70. PubMed | Google Scholar

  17. Omuse G, Maina D, Hoffman M, Mwangi J, Wambua C, Kagotho E et al. Metabolic syndrome and its predictors in an urban population in Kenya: a cross-sectional study. BMC Endocr Disord. 2017; 17: 37. Google Scholar

  18. Kaduka LU, Kombe Y, Kenya E, Kuria E, Bore JK, Bukania ZN et al. Prevalence of metabolic syndrome among an urban population in Kenya. Diabetes Care. 2012 Apr; 35(4): 887-93. PubMed | Google Scholar

  19. Dimodi HT, Etame LS, Nguimkeng BS, Mbappe FE, Ndoe NE, Tchinda JN et al. Prevalence of metabolic syndrome in HIV-infected Cameroonian Patients. World J AIDS. 2014; 4: 85-92. Google Scholar

  20. Kagaruki G, Kimaro G, Mweya C, Kilale A, Mrisho R, Shao A et al. Prevalence and risk factors of metabolic syndrome among individuals living with HIV and receiving antiretroviral treatment in Tanzania. Br J Med Med Res. 2015 Jan 10; 5(10): 1317-27. Google Scholar

  21. Berhane T, Yami A, Alemseged F, Yemane T, Hamza L, Kassim M et al. Prevalence of lipodystrophy and metabolic syndrome among HIV positive individuals on Highly Active Anti-Retroviral treatment in Jimma, South West Ethiopia. Pan Afr Med J. 2012; 13: 43. PubMed | Google Scholar

  22. Erasmus RT, Soita DJ, Hassan MS, Blanco-Blanco E, Vergotine Z, Kegne AP et al. High prevalence of diabetes mellitus and metabolic syndrome in a South African coloured population: baseline data of a study in Bellville, Cape Town. South Afr Med J Suid-Afr Tydskr Vir Geneeskd. 2012 Oct 8;102(11 Pt 1): 841-4. PubMed | Google Scholar

  23. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009 Oct 20; 120(16): 1640-5. PubMed | Google Scholar

  24. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein and [corrected] hypoadiponectinemia. Diabetes Care. 2007 Jan; 30(1): 113-9. PubMed | Google Scholar

  25. Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guelar A, Gimeno JL et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics and related factors. Diabetes Care. 2005 Jan; 28(1): 132-7. PubMed | Google Scholar

  26. Hansen BR, Petersen J, Haugaard SB, Madsbad S, Obel N, Suzuki Y et al. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med. 2009 Jul 1; 10(6): 378-87. PubMed | Google Scholar

  27. Santos A-C, Barros H. Impact of metabolic syndrome definitions on prevalence estimates: a study in a Portuguese community. Diab Vasc Dis Res. 2007 Dec 1; 4(4): 320-7. PubMed | Google Scholar

  28. Paula AA, Falcão MC, Pacheco AG. Metabolic syndrome in HIV-infected individuals: underlying mechanisms and epidemiological aspects. AIDS Res Ther. 2013 Dec 13; 10(1): 32. PubMed | Google Scholar

  29. Carr DB, Utzschneider KM, Hull RL, Kodama K, Retzlaff BM, Brunzell JD et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program adult treatment panel III criteria for the metabolic syndrome. Diabetes. 2004 Aug; 53(8): 2087-94. PubMed | Google Scholar

  30. Price J, Hoy J, Ridley E, Nyulasi I, Paul E, Woolley I. Changes in the prevalence of lipodystrophy, metabolic syndrome and cardiovascular disease risk in HIV-infected men. Sex Health. 2015 Jun; 12(3): 240-8. PubMed | Google Scholar